Effect of L-carnitine supplementation on secondary hyperparathyroidism and bone metabolism in hemodialyzed patients

Calcified Tissue International

Volumn 81, Issue 2, 2007, Pages 99-106

  Cibulka, Roman ^a   Racek, Jaroslav ^a   Pikner, Richard ^a   Rajdl, Daniel ^a   Trefil, Ladislav ^a   Vesela, Eugenie ^b   Studenovska, Marie ^b   Siroka, Romana ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Dialysis Centers EuroCare   (Czech Republic)

Author keywords

Bone metabolism; Hemodialysis; L Carnitine; Osteoprotegerin; Secondary hyperparathyroidism

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; CARNITINE; OSTEOCALCIN; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHOSPHATE; PLACEBO;

ADULT; ARTICLE; BONE METABOLISM; BONE TURNOVER; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG MECHANISM; FEMALE; HEMODIALYSIS PATIENT; HORMONE BLOOD LEVEL; HUMAN; HYPERPARATHYROIDISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SUPPLEMENTATION; TREATMENT OUTCOME;

AGED; BONE AND BONES; BONE DENSITY; CALCIUM; CARNITINE; DIETARY SUPPLEMENTS; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE; MALE; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS; OSTEOPROTEGERIN; PHOSPHATES; RENAL DIALYSIS; TREATMENT OUTCOME; UP-REGULATION;

EID: 34547769913     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-007-9041-1     Document Type: Article

References (35)

1. Schonekess BO, Allard MF, Lopaschuk GD (1995) Propionyl L-carnitine improvement of hypertrophied heart function is accompanied by an increase in carbohydrate oxidation. Circ Res 77:726-734
2. Vaz FM, Wanders R (2002) Carnitine homeostasis and human disease: advances in metabolite analysis. LabMedica 19:14-17
3. Battistella PA, Angelini C, Vergani L, Bertoli M, Lorenzi S (1978) Carnitine deficiency induced during hemodialysis. Lancet 1:939
4. Bohmer T, Bergrem H, Eiklid K (1978) Carnitine deficiency induced during intermittent haemodialysis for renal failure. Lancet 1:126-128
5. Evans AM, Faull R, Fornasini G, Lemanowicz EF, Longo A, Pace S, Nation RL (2000) Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis. Clin Pharmacol Ther 68:238-249
6. Suzuki Y, Nariata M, Yamazaki N (1982) Effects of L-carnitine on arrhythmias during hemodialysis. Jpn Heart J 23:349-359
7. Goral S (2001) Levocarnitine's role in the treatment of patients with end-stage renal disease: a review. Dial Transplant 30:530-538
8. Horl WH (2004) The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. Nephrol Dial Translpant 19(suppl 5):V2-V8
9. 3 by phosphorus in normal men. J Clin Invest 83:1494-1499
10. Portale AA, Booth BE, Halloran BP, Morris RC Jr (1984) Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 73:1580-1589
11. Combe C, Aparicio M (1994) Phosphorus and protein restriction and parathyroid function in chronic renal failure. Kidney Int 46:1381-1386
12. Slatopolsky E, Brown A, Dusso A (2001) Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 37(suppl 2):S54-S57
13. Adamek G, Felix R, Guenther HL, Fleisch H (1987) Fatty acid oxidation in bone tissue and bone cells in culture. Characterization and hormonal influences. Biochem J 248:129-137
14. Ahmad S, Robertson HT, Golper TA, Wolfson M, Kurtin P, Katz LA, Hirschberg R, Nicora R, Ashbrook DW, Kopple JD (1990) Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects. Kidney Int 38:912-918
15. Nakazawa R, Furuhashi S, Shioda T, Kawamura K, Kimura K, Azuma N, Suzuki M (2002) Effect of long-term L-carnitine supplementation on hyperphosphatemic hemodialysis patients [abstract]. Presented at the 11th International Congress on Nutrition and Metabolism in Renal Disease, Nagoya, Japan, March 29-31, 2002
16. Vesela E, Racek J, Trefil L, Jankových V, Pojer M (2001) Effect of L-carnitine supplementation in hemodialysis patients. Nephron 88:218-223
17. Khosla S (2001) The OPG/RANKL/RANK system. Endocrinology 142:5050-5055
18. Kostenuik PJ (2005) Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 5:618-625
19. Seim H (1998) Carnitine. In: Lothar T (ed), Clinical Laboratory Diagnostics. TH-Books Verlagsgesellschaft, Frankfurt, 202-207
20. National Kidney Foundation (2003) Kidney Disease Quality Outcomes Initiative (K/DOQI) clinical practice guidelines. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(suppl 3):S1-S201
21. Locatelli F (2004) The need for better control of secondary hyperparathyroidism. Nephrol Dial Translpant 19(suppl 5):V15-V19
22. Guarnieri G, Toigo G, Crapesi L, Situlin R, Del Bianco MA, Corsi M, LoGreco P, Paviotti G, Mioni G, Campanacci L (1987) Carnitine metabolism in chronic renal failure. Kidney Int 32(suppl 22):S116-S127
23. Urena P, De Vernejoul MC (1999) Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 55:2141-2156
24. Martin KJ, Olgaard K; Bone Turnover Work Group (2004) Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis 43:558-565
25. Charhon SA, Delmas PD, Malaval L, Chavassieux PM, Arlot M, Chapuy MC, Meunier PJ (1986) Serum bone Gla-protein in renal osteodystrophy: comparison with bone histomorphometry. J Clin Endocrinol Metab 63:892-897
26. Sebert JL, Ruiz JC, Fournier A, Fardellone P, Gueris J, Marie A, Moriniere P, Codet MP, Renaud H (1987) Plasma bone Gla-protein: assessment of its clinical value as an index of bone formation in hemodialyzed patients. Bone Miner 2:21-27
27. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319
28. Steddon SJ, Fan SL, Cunningham J (2005) New prospects for the management of renal bone disease. Nephron Clin Pract 99:c1-c7
29. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR (2001) The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16:348-360
30. Nakashima A, Yorioka N, Doi S, Takasugi N, Shigemoto K, Kohno N (2006) Osteoprotegerin and bone mineral density in hemodialysis patients. Osteoporos Int 17:841-846
31. Kazama JJ, Kato H, Sato T, Shigematsu T, Fukagawa M, Iwasaki Y, Gejyo F (2002) Circulating osteoprotegerin is not removed through haemodialysis membrane. Nephrol Dial Transplant 17:1860-1861
32. Avbersek-Luznik I, Malesic I, Rus I, Marc J (2002) Increased levels of osteoprotegerin in hemodialysis patients. Clin Chem Lab Med 40:1019-1023
33. Lee SK, Lorenzo JA (1999) Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 140:3552-3561
34. Avbersek-Luznik I, Balon BP, Rus I, Marc J (2005) Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? Nephrol Dial Transplant 20:566-570
35. Colucci S, Mori G, Vaira S, Brunetti G, Greco G, Mancini L, Simone GM, Sardelli F, Koverech A, Zallone A, Grano M (2005) L-Carnitine and isovaleryl L-carnitine fumarate positively affect human osteoblast proliferation and differentiation in vitro. Calcif Tissue Int 76:458-465